Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?
Multiple Myeloma (MM) is an incurable malignant plasma cell disorder. We have evaluated the counts of Multiple Myeloma Cells (MMCs) and normal plasma cells (N-PCs), seven days after high-dose melphalan (HDM) and autologous stem transplantation (ASCT). Two third of patients had detectable minimal res...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Online |
Language: | English |
Published: |
Impact Journals LLC
2012
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539173/ |